sorafenib has been researched along with Heart Failure in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Armenian, S; Choo, S; Fradley, M; Guha, A; Kuo, D; Kutty, S; Ky, B; Leger, K; Narayan, HK; Sheline, K; Tremoulet, A; Wong, V; Yoon, J | 1 |
| Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H | 1 |
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| Pitoia, F | 1 |
| Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L | 1 |
| Ha, AS; Imran, TF; Joseph, J; Shah, R; Thomas, R | 1 |
| Jarkowski, A; Wong, MK | 1 |
| Chen, MH | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Geisberg, C; Pentassuglia, L; Sawyer, DB | 1 |
| Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M | 1 |
| Rose, S | 1 |
4 review(s) available for sorafenib and Heart Failure
| Article | Year |
|---|---|
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab | 2009 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2012 |
1 trial(s) available for sorafenib and Heart Failure
| Article | Year |
|---|---|
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left | 2015 |
7 other study(ies) available for sorafenib and Heart Failure
| Article | Year |
|---|---|
Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration.
Topics: Antineoplastic Agents; Child; Heart Failure; Humans; Hypertension; Protein Kinase Inhibitors; Sorafenib; Tyrosine Kinase Inhibitors; United States; United States Food and Drug Administration | 2023 |
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Treatment Outcome | 2017 |
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2014 |
Heart failure associated with small molecule tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2016 |
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intolerance; Heart Failure; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2013 |